Compare Summit Therapeutics Inc (SMMT) vs Victoria's Secret & Co (VSXY) Price & Performance

Summit Therapeutics (SMMT) trades at $13.50, down 2.24% on the day, reflecting a bearish technical trend amid negative profitability. The company reported a net loss of $1.08 billion for 2025, with deeply negative ROE and ROA, though a recent asset sale and positive clinical trial data for its oncology candidate provide some operational catalysts. Cash flow remains volatile, with net cash flow turning negative in 2026 projections.

The investment case is binary, hinging on the success of ivonescimab. While analyst consensus is bullish with a $15.57 price target, high volatility and ongoing fiduciary investigations pose significant risks. The stock offers high-reward potential for risk-tolerant investors betting on clinical success, but fundamental weaknesses and cash burn necessitate caution.

Victoria's Secret (VSXY) trades at $87.09, up 6.92% on the day, with a bullish technical signal and strong earnings beats in recent quarters. The stock shows improving fundamentals with revenue stabilizing at $6.23B in 2025 and net income recovering to $165M. Analyst consensus is bullish with a $88.56 price target, and institutional interest is growing, evidenced by Bessemer Group's increased stake in Q1 2026.

The outlook remains positive driven by international expansion, particularly in China, and product innovation. Risks include competitive pressures in retail and margin volatility. With no sell ratings from analysts and strong shareholder support for management, VSXY presents a growth opportunity, though investors should monitor execution on guidance and macroeconomic impacts on consumer spending.